Last reviewed · How we verify
Megace F
Megace F is a Small molecule drug developed by Boryung Pharmaceutical Co., Ltd. It is currently in Phase 1 development.
Megace F is a small molecule medication used to treat conditions such as cachexia, anorexia, and various types of cancer. It is available in different forms, including Megace F and Megace OS, and has been studied in clinical trials for its pharmacokinetics and safety.
-
Baseline phase 1 → approval rate
+9.6pp
Industry-wide phase 1 drugs reach approval ~9.6% of the time (BIO/Informa 2023 industry benchmark across all therapeutic areas).
| Regulator | Country | Likely year | Lag vs FDA |
|---|---|---|---|
| FDA | US | 2033–2036 | — |
| EMA | EU | 2034–2037 | +0.7 yr |
| MHRA | GB | 2034–2037 | +0.7 yr |
| Health Canada | CA | 2034–2038 | +0.9 yr |
| TGA | AU | 2034–2038 | +1.2 yr |
| PMDA | JP | 2034–2038 | +1.5 yr |
| NMPA | CN | 2035–2039 | +2.3 yr |
| MFDS | KR | 2034–2038 | +1.4 yr |
| CDSCO | IN | 2034–2039 | +1.8 yr |
| ANVISA | BR | 2035–2039 | +2.3 yr |
Hover any row for the lag rationale. Lag estimates are reduced when the drug has FDA Breakthrough or EMA PRIME designation (sponsors file globally in parallel).
Estimate based on the BIO/Informa industry phase transition rates plus per-drug modifiers for therapeutic area, sponsor type, FDA designations, mechanism, and trial design. Per-jurisdiction lags from Tufts CSDD international approval studies. Not investment, clinical or regulatory advice. Methodology: /methodology#likelihood.
At a glance
| Generic name | Megace F |
|---|---|
| Sponsor | Boryung Pharmaceutical Co., Ltd |
| Modality | Small molecule |
| Phase | Phase 1 |
Approved indications
Common side effects
Key clinical trials
- Phase 2 Cachexia Clinical Trial to Evaluate the Efficacy and Safety of ASCA101 (PHASE2)
- Megestrol in Treating Patients With Endometrial Neoplasia or Endometrial Hyperplasia (PHASE2)
- Pharmacokinetics of Megace F and Megace OS Under Fasting and Fed Conditions in Healthy Male Volunteers (PHASE1)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Megace F CI brief — competitive landscape report
- Megace F updates RSS · CI watch RSS
- Boryung Pharmaceutical Co., Ltd portfolio CI
Frequently asked questions about Megace F
What is Megace F?
Who makes Megace F?
What development phase is Megace F in?
Related
- Manufacturer: Boryung Pharmaceutical Co., Ltd — full pipeline
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing